Dow Jones
32.394,25 -37,83 (-0,12%) Nasdaq
11.716,08 -52,76 (-0,45%) Nikkei 225
27.563,28 +45,03 (+0,16%) EUR/USD
1,0848 +0,0001 (+0,01%) Bitcoin EUR
25.173,55 +216,42 (+0,87%) CMC Crypto 200
599,03 +356,35 (+146,84%)
Valneva SE (VLA.PA)
| Chiusura precedente | 4,7680 |
| Aperto | 4,7800 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 4,6080 - 4,7800 |
| Intervallo di 52 settimane | 4,4200 - 18,9200 |
| Volume | |
| Media Volume | 388.107 |
| Capitalizzazione | 666,35M |
| Beta (5 anni mensile) | 1,01 |
| Rapporto PE (ttm) | 5,97 |
| EPS (ttm) | 0,7800 |
| Prossima data utili | 04 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,10 |
- GlobeNewswire
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales and €29.6 million of COVID-19 vaccine sales€246.5 million of Other Revenues, primarily driven by revenue recognition related to previous COVID-19 vaccine supply agreements Strong cash position of €289.4 million at December 31, 2022 Raised over €190 million in equity: €102.9 million of gross proceed
- GlobeNewswire
VALNEVA - Declaration of shares and voting rights - February 28, 2023
VALNEVA Declaration of shares and voting rightsFebruary 28, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change wa
- GlobeNewswire
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
Saint-Herblain (France), March 2, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators. On Febru
